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The increasing prevalence of diabetes and its related complications is raising the need for effective meth-
ods to predict patient evolution and for stratifying cohorts in terms of risk of developing diabetes-related
complications. In this paper, we present a novel approach to the simulation of a type 1 diabetes popula-
tion, based on Dynamic Bayesian Networks, which combines literature knowledge with data mining of a
rich longitudinal cohort of type 1 diabetes patients, the DCCT/EDIC study. In particular, in our approach
we simulate the patient health state and complications through discretized variables. Two types of mod-
els are presented, one entirely learned from the data and the other partially driven by literature derived
knowledge. The whole cohort is simulated for fifteen years, and the simulation error (i.e. for each
variable, the percentage of patients predicted in the wrong state) is calculated every year on independent
test data. For each variable, the population predicted in the wrong state is below 10% on both models over
time. Furthermore, the distributions of real vs. simulated patients greatly overlap. Thus, the proposed
models are viable tools to support decision making in type 1 diabetes.
 2015 Elsevier Inc. All rights reserved.1. Introduction
The increasing burden of health care costs is pushing the scien-
tific community towards the development of computational tools
to support decision-making when defining health policies, such
as population screening and new drug interventions, by taking into
account the progression of diseases and healthcare costs. To this
end, decision analysis, pharmaco-economics and outcomes
research have developed, and are increasingly using, simulation
models to derive predictions about health outcomes in target pop-
ulations. The most popular approach is probably represented by
the so-called Markov analysis, which models the time course of a
health condition with a probabilistic finite-state discrete-time
representation [1]. According to this model, a cohort of patients
is simulated by sampling a group of virtual subjects from an initial
probability distribution. The temporal evolution of the simulated
patients is then obtained by sampling, at each discrete time point,
the state of a patient conditioned on his/her state in the previous
time point in accordance to a transition probability matrix, whichcan be variant over time. Other approaches include probabilistic
models based on risk prediction equations, which express the tran-
sition probabilities through (potentially nonlinear) functions of a
number of variables, whose Cartesian product forms the actual
state of the patient [2].
Although Markov models and risk-prediction equations are
widely accepted and certainly very valuable tools, they both suffer
from some methodological drawbacks. On the one hand, Markov
models work well when the number of states is relatively low, i.
e. when it is possible to describe the patients conditions with very
few discrete variables, whose Cartesian product represents the
patient state. Otherwise, serious representational and computa-
tional issues, including the need for learning large joint probability
tables, may occur [3]. On the other hand, risk prediction equations
often implicitly represent the state of a patient by expressing the
dynamics of the outcome variables as a function of time-
dependent observable predictors. This implies that these models
may only be able to perform one-step-ahead predictions, unless a
set of equations is available to forecast the evolution of the predic-
tors [2]. Moreover, sometimes such equations may be semantically
unclear, in terms of the causality relations expressed between the
modeled variables.
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uncertainty is represented by Bayesian Networks (BNs) [4] and
their temporal counterpart, Dynamic Bayesian Networks (DBNs)
[5,6]. DBNs can parsimoniously represent Markov models, thanks
to their ability to decompose the transition matrices into local
probability tables [3]. DBNs can be used, without losing generality,
to represent complex problems and to embed risk prediction equa-
tions, as well as transition probabilities, into a sound probabilistic
framework. Rather surprisingly, while DBNs have been successfully
exploited in bioinformatics, only few simulation models based on
DBNs have been proposed in the literature on long-term diseases
modeling [7,8].
Diabetes Mellitus (DM) is a metabolic disorder that represents
one of the most prevalent diseases in industrialized countries
and an increasing burden in the developing regions. The estimated
prevalence of diabetes during 2014 was 387 million of individuals,
representing 11% (612 billions US $) of the world-wide health care
costs [9,10]. By 2035, the prevalence of diabetes is expected to
increase substantially, with up to 592 million individuals affected
and with an estimated cost for the global economy of 627 billions
US $ [9,10]. DM is a condition primarily defined by the level of
hyperglycemia, which gives rise to the increased risk of micro-
and macro-vascular complications including retinopathy,
nephropathy and neuropathy. Most of the cost associated with
DM is related to the management of these complications [10,11].
In the clinical context of the diabetic patient management and
treatment, it is thus of particular interest to predict the dynamics
of DM complications and to perform simulation analyses about
the potential effectiveness of specific therapeutic interventions.
Some tools are currently available to deal with these tasks. The
Economic Assessment of Glycemic control and Long-term Effects of
diabetes (EAGLE) model provides clinicians with a flexible and
comprehensive tool for the simulation of the long-term effects of
Diabetes treatment and related costs in Type 1 Diabetes (T1D)
and Type 2 Diabetes (T2D) [2,12,13], with risk equations for the
probability of complications based on regression analysis. The
CORE model [14,15] shares similarities of objective with EAGLE
and is based on interdependent Markov models, which simulate
the complications of diabetes and nonspecific mortality using time,
state, and diabetes type-dependent probabilities [10]. Other useful
instruments are represented by the UK Prospective Diabetes Study
(UKPDS) Outcomes Model [16–18] and by the UKPDS Risk Engine
[19], both specific for the progression of T2D. The former is a com-
puter simulation model designed to assess the total burden of the
disease over an extrapolated lifetime for diabetic populations; the
latter is a cardiovascular risk calculator based on 53,000 patients
years of data from the UKPDS cohort [20].
In our paper, we focus our attention on the problem of deriving
a probabilistic simulator of the progression of T1D and its compli-
cations (Diabetic Nephropaty [DN] and Cardiovascular Disease
[CVD]), by learning a DBN with a rich data set coming from the
Diabetes Control and Complications Trial (DCCT) [21] and Epidemiol-
ogy of Diabetes Interventions and Complications (EDIC) [22]
studies, comprising 1441 patients. Retinopathy and neuropathy
are not considered in our model, since data were not sufficiently
complete for these two complications in the two datasets.2. Methods
Bayesian Networks (BNs) are directed acyclic graphs in which
nodes represent the model variables and edges represent the prob-
abilistic relations between variables. Such relations are quantified
by conditional probability tables of each variable given the values
of its parents in the directed graph. BNs possess strong theoretical
properties as well as efficient algorithms for probabilistic inferenceand learning from data. Dynamic Bayesian Networks (DBNs) are an
extension of BNs that represent the temporal evolution of variables
over time. While nodes in the directed acyclic graph of a DBN still
represent random variables, edges represent probabilistic depen-
dencies between variables across time. The key assumption is that
the probability distributions describing the temporal dependencies
are time invariant, so that the temporal evolution of the analyzed
process can be reconstructed by knowing the temporal dependen-
cies represented in the DBN graph [6,23]. In this paper we will
exploit discrete-space/discrete-time DBNs: each node has a finite,
discrete number of states e.g. high, medium, low, and DBNs relate
variables to each other over a discrete number of time steps, called
time slices. For example, Body Mass Index (BMI) at time t  1 influ-
ences the state of Blood Pressure at time t. In this work, the chosen
time pace is one year, given the frequency at which data were
collected on DCCT and EDIC patients. The assumption that the
temporal dependencies are time invariant implies that the DBN is
fully described by representing the variables relationships and
the probability distributions between a single time-slice and its
antecedent, together with the probability distribution of the nodes
at time t = 0. Rather interestingly, DBNs allow encoding cycles and
feedbacks between variables when considering their relationships
over different time slices. In other words, even if cycles are still for-
bidden in a single time slice as in BNs, they may happen when we
consider two or more time slices. Such cycles are clear when the
DBN is rolled-up, i.e. when dependences are shown by representing
each node as a single variable without the time index.
A simplification that greatly enhances computational perfor-
mance when learning large networks is represented by preventing
DBNs from having edges between variables measured at the same
time. In this case, learning the DBNs structure turns out to be much
simpler than learning BNs, since, being not necessary to check that
the resulting graph will be acyclic, it is possible to learn the depen-
dences one node at a time.
In the paper we exploit a set of published algorithms for learn-
ing the conditional probability tables and for learning the structure
of the DBN [24–26]. Our simulations are developed in Matlab
R2014b, with Bayes Net, Statistics and Machine Learning
Toolboxes.
2.1. Data set
To learn the structure and probability distributions of our
Dynamic Bayesian Network we relied on data from two well
known longitudinal studies, DCCT and its follow up, EDIC. DCCT
subjects were randomized to conventional (CT) or intensive dia-
betes therapy (IT), with the latter focusing on maintaining tight
bounds on pre- an post-meal glucose levels and glycated hemoglo-
bin (HbA1c) ranges. The DCCT study was followed by a transitional
period, during which the conventional treatment group was
trained to the use of intensive therapy, and subsequently by an
observational study of the DCCT cohort, the EDIC study. More than
90% of DCCT participants were followed in EDIC as well, allowing
the collection of long-term type 1 diabetes data. The total number
of patients in the resulting DCCT/EDIC data set is 1441.
Relying on previous literature works [2,12–15,27] and on data
availability in the DCCT/EDIC dataset, we classified the variables
according to three categories: static, dynamic and outcome. A
detailed description of variables is reported in the Supplementary
Material. A static variable is here defined loosely speaking, as a
variable whose value at time t does not depend on its value at time
t  1. Static variables include sex, age, duration, treatment, years-
untreated, smoke and exercise, i.e. both properly static variables,
such as patient gender, and variables that vary in time, but in a
deterministic way (e.g. age) or in dependence on external decisions
(e.g. treatment). Years-untreated refers to a time variable counting
Table 1
List of variables and their relative states and cut-off thresholds.
Variable Cut-offs # of cut-offs States Thresholds
WHR 0.8759 (men) and 0.7637 (women) 1 2 Median
SBP 110 mmHg, 120 mmHg 2 3 Tertiles
LDL 112 mg/dl 1 2 Median
HDL 47 mg/dl (men) and 57 mg/dl (women) 1 2 Median
TRIG 72 mg/dl 1 2 Median
BMI 23.82 kg/m2 and 26.73 kg/m2 2 3 Tertiles
HbA1c 7.23, 8.76 2 3 Tertiles
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Dynamic variables are waist-hip ratio (WHR), glycated hemoglobin
(HbA1c), Systolic Blood Pressure (SBP), Low-Density Lipoprotein
(LDL), High-Density Lipoprotein (HDL), triglycerides (TRIG) and
Body Mass Index (BMI). The outcome variables of our study are
nephropathy and cardiovascular diseases (CVD). Each dynamic
and outcome variable is represented by two DBN nodes (one for
current time t, one for the past time t  1).
2.2. Data preprocessing and imputation
Considering the set of measures of all the variables for a single
patient on a single year as an instance of the dataset, we discarded
the instances for which all the dynamic covariates were missing, in
order to avoid the need for massive imputation. We further chose
to exploit only the first 15 years of observation for each patient,
where the number of missing data was always lower than 20%.
(A detailed description of missing data processing is reported in
the Supplementary Material).
The dataset was split into two subsets of subjects, to be used as
training (90%, 1298 patients) and test (10%, 143 patients) set,
respectively, sampling the test set at random by stratifying
patients according to age, sex and treatment and missing data dis-
tribution, so that missing values in the training and test set exhibit
similar percentages to the ones computed for the entire dataset. 37
and 5 patients developed CVD-related complications in the train-
ing and test sets, respectively, whereas 21 and 3 patients experi-
enced renal insufficiency episodes in training and test sets,
respectively. The training set was used to learn the model and
the test to measure its performance. When imputed, missing val-
ues were processed independently in the training and test set.
Discretization of continuous variables according to guidelines. As
reported in the methods section, we decided to rely on discrete-
state DBNs, thus each continuous variable had to be discretized.
Three discretization criteria for three different variable categories
were adopted:
1. For continuous variables with meaningful cut-offs known from
the literature (WHR, SBP, LDL, HDL, TRIG and BMI), we retained
the number and structure of cut-offs (e.g., one cut-off for
triglycerides, two cut-offs for BMI, two different cut-offs for
HDL in men and women) and replaced the literature values
with the median, for single cut-offs, and the first and second
tertile, for double cut-offs, computed for all subjects in the
training set. The cut-offs are reported in Table 1. Such cut-offs
were found in our initial analyses to exhibit better performance
than the literature cut-offs.
2. HbA1c, being the intervention variable of the DCCT study, is
quantized differently: as three treatment conditions can be
identified during the DCCT/EDIC study, namely the two arms
of DCCT (conventional and intensive diabetes treatment) and
EDIC (self-administered diabetes treatment), each resulting in
a noticeably different HbA1c distribution, we fixed the two
cut-offs which better separate the three distributions. The
cut-offs are reported in Table 1.3. For continuous variables with no clear information on meaning-
ful cut-offs in the literature, i.e. age, duration and years-
untreated, we define a search strategy to identify the optimal
cut-offs: while learning the DBN structure, all combinations of
pairs of cut-offs for the three variables are assessed, among
33th and 66th percentile, 25th and 50th percentile, 25th and
75th percentile or 50th and 75th percentile, and we retain
the combination maximizing the BDeu score of the resulting
network, as described in detail in Section 2.3
2.3. DBN structure design
When learning the DBN structure, we aim at merging data-
driven information with literature derived prior knowledge. We
thus explore two different approaches: a Data-Driven Only net-
work (DDO-DBN) and a network designed with Expert Intervention
(EI-DBN), for which a priori constraints are introduced on the
structure.
DDO-DBN. This network is completely data-driven, though
some logical constraints exist (see Table 2). The variable design
(static and dynamic nodes) and their dependencies (edges) is are
in agreement with the literature [28]. Static nodes cannot be influ-
enced by other nodes, i.e. they can be parent nodes but not child
nodes. Each static variable is represented by one node. Static vari-
ables account, in fact, for factors that are not determined by the
model, such as the fact that a patient grows old (age) or his/her
gender. This means the state of these variables does not depend
on the rest of the model. For example, if patient is a woman, all vir-
tual patients simulating her condition will be women, and this will
not change. This is why static variables cannot be considered child
nodes. The treatment node represents an exception, and it is repre-
sented by a node for time t and a node for t  1 (although an edge
is forbidden between the two) in order to explicitly model the
effect of patient treatment during the current and the previous
years. Treatment can affect only the HbA1c nodes. This design
choice is motivated by the strong influence of treatment on HbA1c
levels, demonstrated in the DCCT study [21]. There are two nodes
for each dynamic variable d, representing the status of d at time t
and t  1, respectively, where t is a positive integer representing
the year (2 < t < 15). A parent–child relationship is forced on each
dynamic variable d such that dðt  1Þ ! dðtÞ. Dynamic dðtÞ nodes
can be children of any static variable. In other words, we assumed
that the state of a physiological variable at time t has to be related
to the state of the same variable at t  1.
Outcome nodes such as nephropathy(t) are the DM complica-
tions to be predicted. As in the case of dynamic variables, there
are two outcome nodes for each measured outcome o, representing
the state of that variable at time t and t  1 respectively. Each oðtÞ
node is forced to be child of its correspondent oðt  1Þ node, and
can be child of every dðtÞ, static and oðt  1Þ nodes, while oðt  1Þ
nodes can never be children nodes.
EI-DBN. The EI-DBN network aims at integrating the data-driven
approach with some literature-based constraints. We assumed that
lipid-related variables [29] as well as blood pressure [29,30], age
Table 2
Nodes and edge constraints in DDO-DBN and EI-DBN.
Type Forced parent edge Forced child edge Possible parent edges Possible child edges
DDO-DBN
Static None None None dðtÞ; oðtÞ
dðt1Þ None dðtÞ None Other dðtÞ; oðtÞ
dðtÞ dðt  1Þ None Static, other dðt1Þ oðtÞ
oðt1Þ None oðtÞ None Other oðtÞ
oðtÞ oðt1Þ None Other oðt1Þ, Static, dðt1Þ None
Treatment(t) None None None dHBA1CðtÞ
Treatment(t-1) None None None dHBA1CðtÞ
Additional EI-DBN rules
CVD(t) CVD(t-1), age, LDL(t), HDL(t), TRIG(t), BMI(t), WHR(t), SBP(t) None Other oðt  1Þ, Static, dðt  1Þ None
Nephropathy(t) Age, treatment(t), years-untreated(t), HbA1c(t) None Other oðt  1Þ, Static, dðt  1Þ None
Treatment(t) None Nephropathy(t) None dHBA1CðtÞ
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role in the development CVD complications. On the other hand,
nephropathy seems to be related with HbA1c and, more in general,
with the glycemic control [32,33]. In fact, the frequency of renal
morphometric abnormalities increases with the diabetes duration
[34]. According to these evidences, the EI-DBN is characterized
by additional constraints to the network topology (Table 2): age,
LDL(t), HDL(t), TRIG(t), BMI(t), WHR(t) and SBP(t) were forced to
be parents of CVD(t); age, treatment(t), years untreated(t) and
HbA1c(t) were forced to be parents of nephropathy(t).
2.4. Learning structure
Both the DDO-DBN and EI-DBN structures are learned from
training data by searching the space of all possible networkFig. 1. DDO-DBNstructures with a Tabu Search algorithm [24], based on the Hill
Climbing step of the Max–Min Hill Climbing (MMHC) algorithm
for Bayesian Networks structure learning described by Tsamardi-
nos et al. [25].
Learning edges. As concerns the structural learning step, for each
node our goal is to find the best combination of parents according
to the likelihood-equivalence Bayesian Dirichlet score with uni-
form priors (BDeu), with Equivalent Sample Size = 5 [25,26]. Note
that the mandatory parents are always included when we measure
the score for a combination of candidate parents, according to the
DDO-DBN and EI-DBN constraints listed above.
The implemented search is stepwise. At each step, a single edge
addition or removal from the optimal parent combination obtained
at the previous step is assessed. Since an edge can be either
present or absent, each combination of n candidate parents canstructure.
Fig. 2. EI-DBN structure.
S. Marini et al. / Journal of Biomedical Informatics 57 (2015) 369–376 373be represented by a binary vector p of size n (the forced parents are
not considered in p.) As a starting step, we assume no candidate
parents, i.e. we compute the BDeu score for a node considering
only the edges of its forced parents. We then proceed by evaluating
n possible steps, each determined by flipping a single binary value
of p. For example, if we begin a search for a node with n ¼ 3, then
p ¼ ½0;0;0, the very first considered steps are ½1; 0;0; ½0;1;0 and
½0;0;1 and the step associated with the highest BDeu score is
selected. When computing the score of each step, however, the
vector p is compared to the elements of a Tabu list with maximum
size t. If p is already present in the Tabu list, its score is set as Inf .
If not, p is pushed into the Tabu list. Once the list is full, new
vectors push out the previously inserted ones, following a first-
in-first-out approach. If more than s steps are calculated without
a BDeu score improvement, the search stops. We set t = 100 and
s = 15, according to the literature [25]. Note that in the original
MMHC algorithm the edges, at each step, could undergo three pos-
sible perturbations, namely addition, removal or reversal. In our
case, however, edge direction is fixed, so there is no need to test
for edge reversal. Furthermore, our network is acyclic by construc-
tion. This yields to twomajor consequences: on the one hand, there
is no need to check for acyclicity after every step of the Tabu Search
algorithm; on the other hand, the optimal parent set for each node
can be identified independently of the other nodes, thus greatly
reducing computational complexity.
Learning thresholds. As previously mentioned, one of the goals of
our structure learning procedure is also to find optimal discretiza-
tion cut-offs for the three variables age, duration and years-
untreated. We learn edges (as explained above) for every possible
combination of four cut-off pairs for the three variables, thusTable 3
Percentile cut-offs selected for DDO-DBN and EI-DBN.
DDO-DBN EI-DBN
Low High Low High
Age (%) 25 50 25 75
Duration (%) 33 66 50 75
Years untreated (%) 33 66 25 50testing 3 4 ¼ 81 combinations. For each cut-off combination
the whole DBN score is calculated as the sum the BDeu score of
each individual node.3. Results
Following the procedure explained in the Methods section, we
obtained the DDO-DBN and EI-DBN structures shown in Figs. 1
and 2, respectively; Table 3 reports the optimal thresholds identi-
fied for the three variables age, duration and years untreated in the
two cases.
It is worth noting that the higher number of edges in EI-DBN
depends on the a priori knowledge injection discussed before.
DDO-DBN, on the other hand, seems to split the output nodes
and creates two separate sub-networks to model the evolution of
nephropathy and CVD. The static nodes exercise and smoke are
excluded from both networks; however, this should not be inter-
preted as lack of causal relationship between such nodes and the
outcomes, but simply as a demonstration that such a relationship
does not emerge from DCCT/EDIC data when our stepwise Tabu
search is applied.
After the structure learning phase, DDO-DBN and EI-DBN have
been validated with the test set. Since our aim is to simulate a
whole DM type 1 cohort, our models should replicate the distribu-
tions of all considered variables along time. We started our simu-
lation at time t = 2 (the second year, providing t = 1 data to the
t  1 nodes). For each real patient, we replicated 1000 simulated
patients with the very same node states (resulting in
143 1000 ¼ 143;000 simulated patients). We let the simulated
patients evolve for 15 years and compared the simulated cohort
with the real one every year (time step). Therefore, we measured
for each year (a) the state error, showing how much the simulated
population differs from the real one, in terms of the percentage of
simulated patients predicted in the wrong state; and (b) the differ-
ence between the real and simulated distributions of each dynamic
and outcome variable, measured as the p-value of a Kolmogorov–
Smirnov (KS) test.
For example, if a binary variable v of patient p at time t has 40%
of the corresponding simulated patients in state 1 and 60% in state
Fig. 3. DDO-DBN, EI-DBN and edgeless network state error on test set.
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Table 4
DDO-DBN, EI-DBN and edgeless network p-values of a Kolmogorov–Smirnov test of the difference between the distributions for each node and each year, computed on the test
set.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Years
DDO-DBN
1 1 1 1 1 0.998 1 1 1 0.897 1 0.999 1 1 1 WHR
0.815 0.418 1 1 0.994 0.999 0.559 0.724 0.907 1 1 1 1 0.547 0.914 HbA1C
0.954 0.522 0.989 0.717 1 0.999 1 0.969 0.474 1 0.998 1 0.836 0.944 0.204 SBP
1 1 0.937 0.869 1 1 1 1 1 0.996 0.844 0.437 0.373 0.838 0.999 LDL
1 1 0.999 1 0.676 1 0.862 1 1 1 0.979 0.887 1 1 1 HDL
1 0.853 1 1 1 1 1 1 1 1 1 1 1 1 1 TRIG
1 0.997 0.923 0.996 1 0.999 1 0.999 1 1 1 1 0.645 0.955 0.996 BMI
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 CVD
1 1 1 1 1 0.905 1 0.995 1 0.947 0.995 1 1 0.998 1 Nephropathy
EI-DBN
1 1 1 1 1 0.995 1 1 1 0.881 1 1 1 1 1 WHR
0.845 0.319 1 1 0.977 0.997 0.698 0.916 0.994 0.998 1 1 1 0.552 0.970 HbA1C
0.965 0.558 0.999 0.703 1 0.992 1 0.847 0.320 0.995 0.992 1 0.873 0.916 0.253 SBP
1 1 0.948 0.872 1 1 1 1 1 1 0.823 0.428 0.369 0.835 0.999 LDL
1 1 1 1 0.637 1 0.670 1 1 1 0.996 0.878 1 1 1 HDL
0.999 0.851 1 1 1 1 1 1 1 1 1 1 1 1 1 TRIG
1 1 0.980 0.999 0.997 0.983 0.997 0.991 1 1 1 1 0.686 0.955 0.990 BMI
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 CVD
1 0.925 1 0.958 1 0.992 1 1 1 0.958 0.980 1 1 1 0.980 Nephropathy
Edgeless network
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 WHR
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 HbA1C
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 SBP
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 LDL
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 HDL
0.994 1.000 0.355 0.606 0.077 0.074 0.573 0.302 0.412 0.402 0.208 0.421 0.235 0.368 0.925 TRIG
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 BMI
1 1 1 1 1 1 1 0.992 0.992 0.990 0.991 0.990 0.990 0.998 0.983 CVD
0.020 0.004 0.004 0.001 0.001 0.018 <0.01 0.008 0.003 0.022 0.007 0.001 <0.01 <0.01 0.046 Nephropathy
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states 1 and 2, respectively, then 15% percent of the population is
wrongly estimated by the model. In this case, the state error is
0.15. Note that we compared the real and predicted cohort on a
yearly basis, while other studies compared them only after the
end of the simulation [10,35].
The KS test allows evaluating the equality of distributions [36].
It can be applied to compare two samples (two samples test) or a
sample with a corresponding reference distribution (one sample
test). In the present study the two samples test is applied in order
to determine whether each variable in simulated patients show an
overlapping distribution with its counterpart in real patient.
As baseline comparison we calculated the state errors and KS
test p-values of a null model without edges between variables
(i.e. a edgeless network). Fig. 3 shows the error calculated over
the 15 years period for DDO-DBN, EI-DBN and the edgeless
network; Table 4 reports the respective KS test p-values.
As it is clear from Fig. 3, both DDO and EI network show a very
low error for the whole 15-years period, especially if compared to
the edgeless network. The population predicted in the wrong state
is below 10% on both DDO-DBN and EI-DBN, while it goes up to
90% in the edgeless network. As shown by the p-values of Table 4,
there are no significant differences (p > 0:05) between the DDO-
DBN and EI-DBN simulations and the real one, with many nodes
having p-values higher than 0.9; on the other hand, the edgeless
network has very low p-values, showing how such a model fails
to replicate real data distributions, which are significantly different
from the real ones (p < 0:01). A notable exception is represented
by the CVD node. This may be due to the relatively low number
of CVD occurrences in the test population (see Section 2.2). How-
ever, the state error clearly shows how the edgeless network
predictions are outperformed by DDO-DBN and EI-DBN even on
the CVD node.By comparing DDO-DBN and EI-DBN, we can infer they are basi-
cally equally powerful in predicting the states of the modeled
nodes. In fact, the average error obtained by the DDO-DBN network
is only 0.3% lower than the one of the EI-DBN network. This looks
quite interesting, since it shows that different models turns out to
explain equivalently well the data.
4. Discussion
In this paper, we presented a novel approach to the simulation
of development of clinical complications in a type 1 diabetes
cohort, based on Dynamic Bayesian Networks. Our models were
learned from a rich dataset, composed of the DCCT and EDIC stud-
ies, and their performance was assessed on an independent test
set. Biases in the test set were limited by sampling it with stratifi-
cation, according to several major variables, and by excluding the
test set from the whole patient set before the learning step.
Our models were built by integrating medical a priori knowl-
edge, such as the cut-offs structure for variable discretization
thresholds and the forced dependencies between variables in the
network structure, with data mining techniques, like the Tabu
search algorithm used to learn the empirical discretization cut-
offs and the network structure. A priori information on network
structure was provided following two types of approaches: a fully
agnostic approach (Data-Driven Only network, DDO-DBN), forcing
just the minimal relations between the variables, and a fully
informed approach (Expert Intervention network, EI-DBN), forcing
all known relations between the variables and the outcomes.
Tested on independent data, the two networks were shown to
(a) correctly replicate the population state trajectories of both
the outcome variables (nephropathy and CVD) and the dynamic
variables (WHR, HbA1c, SBP, LDL, HDL, TRIG and BMI), exhibiting
an error rate lower than 10% over a 15 years period; (b)
376 S. Marini et al. / Journal of Biomedical Informatics 57 (2015) 369–376significantly outperform a baseline model with no edges between
the variables and (c) exhibit very similar performance in predicting
the patients evolution.
A major strength of our approach, as opposed to many of the
similar approaches in the literature, is the explicit representation
of the relations between the different risk factors and the pathways
along which each risk factor influences the final outcomes. This
could be used to tailor better patient-specific interventions, by
studying the temporal evolution of risk factors and the estimated
alteration of the different variable pathways.
The major limitations of our approach probably derive from its
discrete nature: all variables are discretized in a limited number of
states and time is discretized in temporal slices of one year. This
yields to predictions of variable evolution that are partly qualita-
tive, indicating just the most probable range for each continuous
variable and preventing a temporal resolution smaller than one
year. Nevertheless, we believe that such results could be useful
in a clinical setting, to estimate the evolution of a type 1 diabetes
cohort and to stratify patients according to their probability of
developing complications in the near or far-off future.
In terms of future directions, we plan to implement our model
in a web-based tool, which will both improve its accessibility by
non-technical users and facilitate the possible further validation
of the model with external type 1 diabetes cohorts.Conflict of interest
None declared.Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jbi.2015.08.021.
These data include MOL files and InChiKeys of the most important
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